Bevacizumab

LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, Norway and Liechtenstein LYTENAVA™ (bevacizumab gamma) receives ten years of market exclusivity in EU Advancing toward commercial launch of LYTENAVA™ (bevacizumab gamma) in EU expected in calendar Q1 2025 Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in EU May 28, 2024 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that the European Commission has granted Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD in the EU. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU. The application for European Commission Marketing Authorization of LYTENAVA™ (bevacizumab gamma) is a mixed application grounded on Article 8.3 of Directive 2001/83/EC and is based on the results from Outlook’s wet AMD clinical program, which consists of three completed registration clinical trials - NORSE ONE, NORSE TWO and NORSE THREE – as well as studies and peer reviewed literature substituting or supporting certain tests and studies. This decision applies automatically in all 27 EU Member States and, within 30 days, also to Iceland, Norway and Liechtenstein. Additionally, the Marketing Authorization grants Outlook an initial ten years of market exclusivity in the EU for LYTENAVA™ (bevacizumab gamma). “This is a landmark milestone for us. We are extremely pleased to receive Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU and are moving toward our potential first commercial launch in an EU Member State in the first calendar quarter of 2025. The EU represents the second largest wet AMD market in the world, and we look forward to continuing our efforts to bring to the EU market the first and only on-label, ophthalmic bevacizumab for the treatment of wet AMD. We are incredibly grateful to all the patients, researchers, clinical sites and the European Medicines Agency for the research, drug development, and regulatory efforts that led to this approval,” commented Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics. Jedd Comiskey, Senior VP – Head of Europe for Outlook Therapeutics, added, “We believe that LYTENAVA™ (bevacizumab gamma) has the potential to be a meaningful treatment option in the ophthalmology landscape in the EU and are thrilled to focus efforts toward our potential initial launch in the European region. Our team is working hand in hand with our commercialization partner, Cencora, to support our EU launch anticipated in the first calendar quarter of 2025. We look forward to further solidifying our global launch strategy and to an exciting year ahead.” As part of the Company’s multi-year planning process, Outlook Therapeutics entered a strategic collaboration with Cencora (formerly AmerisourceBergen) to support the commercial launch of LYTENAVA globally following regulatory approvals. Cencora will provide comprehensive launch support in Europe including pharmacovigilance, regulatory affairs, quality management, market access support, importation, third-party logistics (3PL), distribution and field solutions. The collaboration and integrated approach will support market access and efficient distribution of LYTENAVA in a way that benefits all stakeholders, including retina specialists, providers and patients that will have efficient access to the product. “We have been working closely with Outlook Therapeutics to develop and execute a global launch strategy and are thrilled to help them bring this therapy to market in Europe,” said John W. Arena, senior vice president of Enterprise Strategy & Solutions on Cencora’s Global Pharma Services team. “We will deliver the integrated solutions needed to support a successful commercial launch and ensure healthcare providers have timely and reliable access to the therapy.” ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission. Outlook has also submitted its Marketing Authorization Application (MAA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) seeking authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD). The submission was completed under the new International Recognition Procedure (IRP). The IRP is available for new UK MAAs of a medicinal product (having the same qualitative and quantitative composition, and the same pharmaceutical form) that has previously been authorized by a Reference Regulator (RR). In this case this is the European Medicines Agency (EMA) Committee on Human Medicinal Products (CHMP). The IRP allows the MHRA to rely on a positive opinion by the CHMP concerning an application for grant of Marketing Authorization for the same product in the EU. In the United States, ONS-5010/LYTENAVA™ is currently being evaluated in an ongoing non-inferiority study for the treatment of wet AMD. Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. Outlook Therapeutics is a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD, DME and BRVO. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD. Outlook is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and has also filed a MAA for ONS-5010 as a treatment for wet AMD in the UK. In the United States, ONS-5010/LYTENAVA™ is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD and if successful, the data may be sufficient for Outlook to resubmit a BLA application to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at investor.cencora.com The content above comes from the network. if any infringement, please contact us to modify.

复宏汉霖复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已在中国上市5款产品，在国际获批上市3款产品，23项适应症获批，3个上市申请分别获中国药监局和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖50多个分子，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。继国内首个生物类似药汉利康®（利妥昔单抗）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、汉达远®（阿达木单抗）和汉贝泰®（贝伐珠单抗）相继获批上市，创新产品汉斯状®（斯鲁利单抗）已获批用于治疗微卫星高度不稳定（MSI-H）实体瘤、鳞状非小细胞肺癌、广泛期小细胞肺癌和食管鳞状细胞癌，并成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。公司亦同步就16个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。技术平台质量体系复宏汉霖已建立有一套符合国际质量标准的质量管理体系，覆盖从项目研发到物料管理、产品生产、质量控制、产品供应链管理以及产品上市后跟踪的全生命周期，为公司产品在多个国家及地区的商业化奠定扎实基础。公司商业化生产基地商业化生产基地及配套的质量管理体系已通过中国国家药监局、欧洲药品管理局（EMA）、美国食药监局（FDA）、欧盟质量受权人（QP）以及公司国际商业合作伙伴进行的多项实地核查及审计，获得中国、欧盟、美国及多个PIC/S成员GMP认证。在富有国际工作经验的管理团队的带领下，复宏汉霖持续优化改进质量体系，改善质量运营效率，奠定了持续改进、不断完善的质量文化。公司新闻汉霖快讯 | 秘鲁获批，汉利康®出海“首战”告捷近期，复宏汉霖自主开发和生产的汉利康®（利妥昔单抗）正式获得秘鲁药监局（Dirección General de Medicamentos, Insumos y Drogas, “DIGEMID”）批准上市，商品名为AUDEXA®。汉利康®成为继汉曲优®和汉斯状®后，复宏汉霖第三款海外获批上市的自主研发和生产的产品。作为中国首个生物类似药，汉利康®自2019年获批上市以来已惠及超25万名中国患者。质量源于设计，又贯穿始终。QbD大会历经四载，在行业同仁的持续关注和支持下，2024第五届QbD生物药质量科学大会（QbD2024）将于7月26-27日在北京悠唐皇冠假日酒店再次召开。将重点围绕创新生物药的质控、分析、法规等内容展开讨论。从案例、实践去解读创新药质量研究管理的进程，持续深化QbD理念。复宏汉霖药政事务高级总监文继川将在大会会场四：生物制品注册专场为大家带来主题为“国产PD-1出海的法规依据解读”的报告，诚邀各位专家莅临指导！药企福利-享免费观摩门票推荐阅读归来花满树，携手再破千层浪！金斯瑞蓬勃生物倾情加盟QbD2024第五届生物药质量科学大会茵冠生物质量总监邹沛华：间充质干细胞质量控制与质量体系的搭建 | QbD2024风云录泽辉生物质量负责人单晓鹏：细胞治疗产品控制策略 | QbD2024风云录原启生物质量副总裁陶铜静：CGT药物CMC质量控制策略 | QbD2024风云录景达生物CEO杨月峰：通用现货型NK细胞的工艺开发及质量控制 | QbD2024风云录贝思奥生物创始人罗光佐：AAV药物关键质量属性及其分析质控难点 | QbD2024风云录祐和医药陈兆荣：遵循监管政策，加速新药研发 | QbD2024风云录明济生物金秀梅：抗体药物杂质研究的思考 | QbD2024风云录